Background
==========

Acute myocardial infarction (AMI) is acute myocardial necrosis caused by persistent and severe myocardial ischemia. Clinical manifestations include persistent severe pain, acute circulatory dysfunction, and arrhythmia. Patients with acute coronary syndrome (ACS) may develop new-onset atrial fibrillation (AF). About 10--20% of patients with AMI have AF \[[@b1-medscimonit-26-e925666],[@b2-medscimonit-26-e925666]\]. New-onset AF often occurs in patients with myocardial infarction and the incidence of AF will increase the rate of complications and mortality and the risk of AF at follow-up \[[@b3-medscimonit-26-e925666]--[@b5-medscimonit-26-e925666]\]. AF is more likely to occur in older patients with AMI and in those with higher Killip class or left ventricular dysfunction \[[@b6-medscimonit-26-e925666]\]. The factors affecting AF onset in the acute phase of MI are left ventricular dysfunction, notably Killip class IV and high heart rate (\>100 bpm) at admission \[[@b7-medscimonit-26-e925666]\]. AF is a common clinical arrhythmia. Long-term restoration and maintenance of sinus rhythm using the currently available antiarrhythmic agents is a clinical challenge.

The 2018 AHA/ACC Guidelines on Management of Blood Cholesterol confirmed the relationship between low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (ASCVD) \[[@b8-medscimonit-26-e925666]\]. The 2019 ESC/EAS Guidelines for the Management of Dyslipidemias recommend the new goal of reaching a 50% LDL-C reduction from baseline and/or \<1.4 mmol/L (\<55 mg/dL) \[[@b9-medscimonit-26-e925666]\]. All ACS patients with no contraindications should be given high-intensity statin therapy, regardless of initial LDL-C values. Statin therapy is recommended as the first-line treatment for primary prevention of ASCVD \[[@b10-medscimonit-26-e925666]\]. The HOPE-3 trial showed the importance of statins in the treatment of atherosclerosis and as secondary prevention in acute myocardial infarction \[[@b11-medscimonit-26-e925666]\]. Statin pretreatment can effectively improve myocardial perfusion in patients with STEMI, can improve the prognosis of coronary heart disease \[[@b12-medscimonit-26-e925666]\], and possibly prevent AF by significantly lowing C-reactive protein levels \[[@b13-medscimonit-26-e925666]\]. Research suggests that statins may potentially prevent or deter AF, irrespective of their effects on lipids, by anti-inflammatory action. Other beneficial effects of statin therapy are seen in controlling inflammation, oxidation, and thrombosis \[[@b14-medscimonit-26-e925666]--[@b16-medscimonit-26-e925666]\]. With more in-depth analysis of the pleiotropic effects of statin in coronary heart disease, the role of statin, in addition to its ability to control lipid level, has also become the focus of basic and clinical researchers. A meta-analysis showed the benefits of statin use, which can prevent AF \[[@b17-medscimonit-26-e925666]\]. High-dose rosuvastatin treatment can reduce the incidence of contrast-induced nephropathy in patients with PCI \[[@b18-medscimonit-26-e925666]\]. Another meta-analysis showed that high-dose rosuvastatin can significantly reduce hs-CRP, LDL-C, and cTnT levels in ACS patients with PCI in China \[[@b19-medscimonit-26-e925666]\]. Although studies showed the benefit of statins in reducing AF occurrence in ACS patients, there is insufficient data on the role of rosuvastatin in reducing new-onset AF in AMI patients. The purpose of the present study was to investigate the effect of 2 dosages of rosuvastatin on the incidence of AF and ischemic events in AMI patients. We also observed the safety of using different dosages of rosuvastatin to determine the optimal dosage of rosuvastatin.

Material and Methods
====================

Data sources and study population
---------------------------------

This was an observational, retrospective cohort study performed in the central and east districts of Shandong Provincial Hospital affiliated to Shandong First Medical University in Jinan, China. The reviewed period was from January 2014 to June 2018. The data were obtained from the medical records database in the Medical Records Department. Using the key words "acute myocardial infarction" and "rosuvastatin", we found 376 cases. The patients were offered optimal medication treatment and 10 mg or 20 mg rosuvastatin. Clinical follow-up by telephone interview, outpatient clinic visit, or at readmission were conducted until the end of the 2019. We recruited 323 patients whose data were comprehensive and complete according to the inclusion criteria. Among them, 175 were offered optimal medication treatment and 10 mg of rosuvastatin, while 148 patients were offered optimal medication treatment and 20 mg of rosuvastatin. There were 236 males and 87 females with an age range of 33--83 years. The main exclusion criteria were: (1) history of AF, (2) hyperthyroidism, (3) moderate-severe rheumatic valvular disease, (4) infectious diseases, immune system diseases, and sepsis, (5) recent use of anti-inflammatory drugs and antioxidant therapy, (6) combined liver and kidney dysfunction and other serious systemic diseases, (7) combined hypertension and diabetes mellitus not treated effectively, (8) other acute or chronic diseases of the blood and cancer, and (9) psychotic. The study was designed by all the authors and was approved by the Ethics Committees at Shandong Provincial Hospital affiliated to Shandong First Medical University. Consent was exempted due to retrospective enrollment.

Treatment
---------

All patients were treated according to the 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction \[[@b20-medscimonit-26-e925666],[@b21-medscimonit-26-e925666]\]. Optimal treatment included antiplatelet, anticoagulant drugs, nitrates, ACEI/ARB, beta blockers, thrombolysis, or/and PCI treatment. Based on the above treatment, the patients were given rosuvastatin (Crestor, Astra Zeneca, USA) treatment once daily after admission. The patients were randomly allocated to receive rosuvastatin 10 mg or 20 mg treatment. A 12-lead electrocardiogram (ECG) was recorded at admission in all patients. Each patient underwent an electrocardiogram at each visit during the study. AF was considered to be rapid oscillations or fibrillatory waves, which vary in size, shape, and time, and are accompanied by irregular ventricular responses. Follow-up was routinely performed by telephone interview or at an outpatient clinic at 1, 3, 6 and 12 months after discharge. During the 12-month follow-up, 24-h Holter ECG monitoring was recorded as needed. AF occurrence during the study was defined as follows: the presence of AF in the ECG performed during each planned clinical visit, AF as a cause of heart dysfunction and/or hospital admission, and AF occurrence during hospitalization. Anticoagulant agents were given to patients if AF occurred during hospitalization or follow-up. Antiarrhythmic drugs were used to reverse sinus rhythm. Blood biochemical variables were closely monitored during medication. Patients stopped taking rosuvastatin if any of the following events occur: myalgia, creatine kinase (CK) more than 5 times the upper limit of normal, alanine aminotransferase (ALT) more than 3 times the normal high limit, and creatinine (Cr) above 221mmol/L. Patients who had chest pain, palpitations, and other symptoms were required to undergo ECG examinations and were admitted to the hospital if needed. The flow diagram of the main procedures is illustrated in [Figure 1](#f1-medscimonit-26-e925666){ref-type="fig"}.

Variables
---------

Total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), creatine kinase (CK), and creatinine (Cr) levels were measured by automatic biochemistry analyzer (AU5800, Beckman Coulter, USA) in the clinical laboratory diagnostic center of Shandong Provincial Hospital affiliated to Shandong First Medical University in Jinan, China. The levels of HDL-C, LDL-C, and CK were measured by HDL-C, LDL-C, and CK Assay Kits, respectively (Directed Method and Phosphocreatine Substrate Method, Weigao Biochemistry, China). The levels of TC and TG were measured by TC and TG Assay Kits, respectively (Enzyme Method and GPO-POD Method, Beckman Coulter, USA). The levels of ALT were measured by ALT Assay Kit (LDH Method, Beckman Coulter, USA). The levels of Cr were measured by Creatinine Assay Kit (Sarcosine oxidase Method, Maccura, China). The main testing procedures were performed following the manufacturer's instructions, including reagent preparation, parameter setting, instrument calibration, operation, quality control, and calculation. We recorded occurrences of paroxysmal, persistent, and permanent atrial fibrillation and ischemic events. Ischemic-related events include heart failure, recurrent hospitalization of coronary heart disease, sudden cardiac death, and ischemic stroke.

Echocardiography
----------------

All studies were performed with echocardiography equipment (Sonos 5500, Philips Medical Systems, Bothell, WA, USA) during admission and 12 months after the use of the drug. Left ventricular end-diastolic diameters (LVDd) was obtained by M-mode echocardiography from the parasternal long axis view, as recommended by the American Society of Echocardiography. The ejection fraction (EF), fractional shortening of the left ventricle (FS), and cardiac output (CO) were calculated by a modified Simpson's method. Data from 3--5 consecutive cardiac cycles were used for analysis \[[@b22-medscimonit-26-e925666],[@b23-medscimonit-26-e925666]\].

Statistical analysis
--------------------

Data are presented as mean±standard deviation and were analyzed by using GraphPad Prism 8.0 and SPSS20.0 statistical analysis software. Each set of data related to 1 drug dosage was compared separately using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test for multiple comparisons or the *t* test for equality of means. Categorical variables, including clinical presentation except age and BMI, medical history, risk factor, current or recent medication, treatment, and outcome events, are presented as number and/or percentage and were compared using the χ^2^ test. Multivariate Cox analysis was used to identify associations between multiple independent predictors and AF and occurrence of ischemia-related events at 12 months and results are expressed as hazard ratio (HR) and 95% confidence interval (CI). Kaplan-Meier curves are presented along with the results of the log-rank test. A P value \<0.05 was considered statistically significant.

Results
=======

Baseline characteristics of patients
------------------------------------

The average age of the study population was 62.3±9.8 years, and 77.1% of patients were men. The differences of diagnosis, age, sex, risk factors, medical history, current or recent medication, and treatment between the 2 groups were not statistically significant. Nevertheless, there were more patients with hypertension in the 10-mg group than in the 20-mg group. Diabetes was the most frequent comorbidity, but there was no statistically significant difference between the 2 groups. More than half of the patients received a β-blocker to control heart rate. After admission, 85.4% of patients were treated with PCI ([Table 1](#t1-medscimonit-26-e925666){ref-type="table"}).

Results of blood lipid of patients
----------------------------------

After treatment with rosuvastatin for 1 and 12 months after discharge, the levels of TC, LDL-C, and TG were significantly lower than those at admission in both the 10-mg and 20-mg groups (P\<0.05). No significant change was found in HDL-C after 1 or 12 months of rosuvastatin treatment (P\>0.05). Compared with the 10-mg group, LDL-C was significantly lower in the 20-mg group at 1 and 12 months (P\<0.05). The LDL-C level was around 1.8 mmol/L at 1 and 12 months in the 20-mg group. The results indicated that rosuvastatin effectively lowered lipid levels, and the effect of 20-mg rosuvastatin being better than that of 10-mg rosuvastatin ([Figure 2](#f2-medscimonit-26-e925666){ref-type="fig"}).

Results of echocardiography of patients
---------------------------------------

Two groups of patients were treated with different dosages of rosuvastatin for 12 months. HR of both groups were significantly lower than before treatment (P\<0.05). While there was no significant difference in LVDd of both groups post-treatment, the 20-mg group showed more improvement in left ventricular function. The LVEF, FS, and CO of the 20-mg group showed significant improvement compared to before treatment (P\<0.05). The FS variable in the 20-mg group had significant increases compared to the 10-mg group at 12 months after treatment (P\<0.05). The results in [Table 2](#t2-medscimonit-26-e925666){ref-type="table"} show the benefit of using rosuvastatin in the treatment of cardiac remodeling and cardiac function.

Comparison of the occurrence of atrial fibrillation
---------------------------------------------------

Two groups of patients were treated with different dosages of rosuvastatin for 12 months. A significant difference in the occurrence rate of atrial fibrillation was observed between the 2 groups. There were 21 cases of paroxysmal atrial fibrillation, 4 cases of persistent atrial fibrillation, and 3 cases of permanent atrial fibrillation in the 10-mg group, for a total of 28 cases (16.0%). There were 8 cases of paroxysmal atrial fibrillation, 2 cases of persistent atrial fibrillation, and 2 cases of permanent atrial fibrillation in 20-mg group, for a total of 12 cases (8.1%). The occurrence rate of AF in the 2 groups was compared by χ^2^ test, and the difference was significant (P=0.032). In addition, Kaplan-Meier survival analysis showed the difference in the occurrence of AF (log-rank test 4.685, P=0.030) at different dosages of rosuvastatin ([Table 3](#t3-medscimonit-26-e925666){ref-type="table"}, [Figure 3A](#f3-medscimonit-26-e925666){ref-type="fig"}).

Comparison of the incidence of ischemic events of patients
----------------------------------------------------------

Two groups of patients were treated with different dosages of rosuvastatin for 12 months. There were 21 cases (12.0%) of ischemic events in the group treated with 10 mg of rosuvastatin, including 12 cases of recurring coronary heart disease, 7 cases of heart failure, and 2 cases of stroke. There were 8 cases (5.4%) of ischemic events in the 20-mg group, including 6 cases of recurring coronary heart disease, 1 case of heart failure, and 1 case of stroke. There were no sudden cardiac deaths in these 2 groups. The incidence of ischemic events in the 2 groups was compared by χ^2^ test. The incidence of ischemic events was significantly different between the 2 groups (P=0.039). In addition, Kaplan-Meier survival analysis also showed the difference (log-rank test 4.277, P=0.039) at different dosages of rosuvastatin ([Table 3](#t3-medscimonit-26-e925666){ref-type="table"}, [Figure 3B](#f3-medscimonit-26-e925666){ref-type="fig"}).

Comparison of the adverse clinical events of patients
-----------------------------------------------------

Adverse clinical events variables included myalgia and creatine kinase (CK), alanine aminotransferase (ALT), and creatinine (Cr). Two groups of patients were treated with different dosages of rosuvastatin for 12 months. There were 5 unsafe events in the 10-mg group and 4 in the 20-mg group. The data were tested by χ^2^ test. [Table 3](#t3-medscimonit-26-e925666){ref-type="table"} shows there was no difference between the 2 groups (P=0.799), suggesting that it was safe to use 20 mg rosuvastatin for 12 months in clinical practice. Kaplan-Meier survival analysis also showed the same result (log-rank test 0.007, P=0.933) ([Figure 3C](#f3-medscimonit-26-e925666){ref-type="fig"}).

Multivariate Cox regression analysis of risk factors for the occurrence of AF and ischemic events
-------------------------------------------------------------------------------------------------

We used multivariate Cox regression analysis to investigate the impact of baseline characteristics associated with new-onset AF after AMI. These results demonstrated that different dosages of rosuvastatin (HR=0.330, 95%CI 0.156--0.698, P=0.004), age (HR=1.045, 95%CI 1.006--1.085, P=0.023), smoking (HR=2.680, 95%CI 1.383--5.193, P=0.003), and drinking (HR=2.285, 95%CI 1.154--4.525, P=0.018) are independent factors associated with occurrence of AF. Different dosages of rosuvastatin (HR=0.303, 95%CI 0.128--0.720, P=0.007), diabetes mellitus (HR=2.953, 95%CI 1.169--7.462, P=0.022), and smoking (HR=2.661, 95%CI 1.230--5.755, P=0.013) are independent factors associated with occurrence of ischemic events ([Table 4](#t4-medscimonit-26-e925666){ref-type="table"}).

Discussion
==========

Statins are the basic drugs used for the treatment of ACS. The optimal dose and safety of statin on patients with ACS have been a hot topic in basic research and clinic practice, especially for rosuvastatin. The results of our study indicated that the administration of rosuvastatin can not only reduce total serum cholesterol and LDL, but also can reduce the incidence rate of new-onset AF and ischemic events in AMI patients. There were no significant differences in the safety of using 2 different doses of rosuvastatin 12 months after admittance. It was found that atrial ischemia, increased left atrial pressure, left atrial enlargement, and left ventricular dysfunction result in ACS and can lead to AF \[[@b7-medscimonit-26-e925666]\]. Previous studies have demonstrated that the mechanisms of rosuvastatin include endothelial function improvement, oxidative stress reduction, and regulation of inflammation and antiarrhythmic effects \[[@b24-medscimonit-26-e925666]\]. The function of the cardiac autonomic nervous system in AF has been of interest in recent years. The imbalanced and inhomogeneous distribution of the sympathetic and pneumogastric nerves is associated with the occurrence and maintenance of AF. A recent study observed the effects of rosuvastatin on effective atrial refractory pacing, the induction of atrial fibrillation, and changes in atrial autonomic nerves in an AF model induced by rapid pacing in rabbits. The results showed that persistent rapid atrial pacing can cause heterogeneous autonomic neural remodeling in different parts of the atrium and can lead to AF, which can be reversed by rosuvastatin \[[@b25-medscimonit-26-e925666]\]. Huang et al. found that in patients receiving statin in clinical practice, the CHADS~2~ score can help identify AMI patients who will benefit from the use of statin to prevent AF \[[@b26-medscimonit-26-e925666]\]. The risk of new-onset AF was decreased by statin use within 1 month after discharge in patients with myocardial infarction or coronary revascularization \[[@b27-medscimonit-26-e925666]\]. According to Pierri et al., 7-day preoperative treatment with statin decreased the incidence of AF after surgery \[[@b28-medscimonit-26-e925666]\]. Recent evidence showed that statins can decrease the risk of stroke proportional to the degree of cholesterol reduction by lowering TC and LDL-C \[[@b29-medscimonit-26-e925666],[@b30-medscimonit-26-e925666]\].

The main pathological feature of atherosclerosis is the deposition of lipid in some parts of the artery, accompanied by smooth muscle cells proliferation and fibrous matrix components. Factors that contribute to atherosclerotic plaque instability include hemodynamic changes, stress, and inflammation \[[@b31-medscimonit-26-e925666]\]. Inflammatory reactions play an important role in unstable plaque and plaque rupture. Statins can not only reduce TC and LDL-C, but can also strengthen collagen formation, thereby increasing plaque stability. Statins contribute to plaque regression by reducing lipid levels \[[@b32-medscimonit-26-e925666]\]. Multivariate Cox analysis in the present study showed that age, smoking, and drinking are independent risk factors associated with the occurrence of AF after adjusting for other factors. Increased plaque instability may be the cause of the incidence of AF, together with smoking, drinking, and older age. Long-term treatment with statins is related to decreased occurrence of plaque rupture detected by OCT in patients presenting with ACS, with a potentially more marked effect in patients with NSTE-ACS \[[@b33-medscimonit-26-e925666]\]. Statins can enhance the production of endothelial-derived NO synthase, increase coronary blood flow, and reduce ischemia reperfusion injury. Our data showed that it can improve heart function by reducing the occurrence of cardiac ischemic events and demonstrated a downward trend of the incidence of AF. The activation of Akt/Nrf2/HO-1 signaling is involved in the suppressive effect of statin on atrial tachypacing-induced cellular remodeling. These results show the protective effect of statin on AF \[[@b15-medscimonit-26-e925666]\]. A meta-analysis of 5 trials with 524 patients was conducted to study the effect of statin agents on the recurrence of AF after electrical cardioversion. Rosuvastatin significantly decreased the frequency of AF recurrence after successful electrical cardioversion \[[@b34-medscimonit-26-e925666]\]. Patel et al. also performed a meta-analysis of 5 randomized and observational studies that reported statins significantly decreased the occurrence rate of AF \[[@b35-medscimonit-26-e925666]\].

The SECURE-PCI trial assessed the impact of using 80 mg atorvastatin on Major Adverse Cardiovascular Events (MACE) before and 24 h after the planned percutaneous coronary intervention (PCI). Results showed that there is a significant 28% relative risk reduction in MACE at 30 days in ACS patients \[[@b36-medscimonit-26-e925666]\]. The PULSAR study demonstrated that 10 mg rosuvastatin treatment was more effective than atorvastatin 20 mg treatment in LDL-C reduction in patients with hypercholesterolemia and there was no significant difference in the occurrence rate of adverse clinical events \[[@b37-medscimonit-26-e925666]\]. It was also reported that equivalent reduction of LDL-C and non-HDL-C required higher dose of atorvastatin and simvastatin than rosuvastatin \[[@b38-medscimonit-26-e925666]\]. High-dose statin pretreatment has an important effect on improving the TIMI flow in patients undergoing PCI, and high-dose statin preloading also reduces the incidence of MACE \[[@b39-medscimonit-26-e925666]\]. High-dose rosuvastatin increases macrophage ATP-binding cassette A1 protein transporter in human atherosclerotic plaque \[[@b40-medscimonit-26-e925666]\]. The results of this study showed that 20 mg per day rosuvastatin treatment can reduce the occurrence rate of ischemic events significantly compared to before treatment. The factors increasing the chance of ischemic events are as follows: male, diabetic, hypertensive, heart failure or occult heart failure, and noncompliance with statins. High-dose statin therapy should be given as soon as possible after admission for AMI patients. However, patients with long-term use of high-dose statins may develop rhabdomyolysis, liver and/or kidney damage and other adverse reactions. During the 12-month follow-up in this study, the clinical and blood biochemical variables of the patients were observed. The results showed that the adverse clinical events were not significantly different between the 10-mg per day rosuvastatin group and the 20-mg per day group at 12 months after admittance. These results suggest that long-term use of 20 mg per day rosuvastatin is safe. Approximately 10% of the dose of rosuvastatin is metabolized by hepatic cytochrome P4502C9. Approximately 90% of it is excreted in the stools (including absorption and active substances not absorbed), while the rest is excreted through the urine. The plasma clearance half-life of rosuvastatin is about 19 h. The half-life of a clearance did not increase with the increase of dose. However, the use of high doses of statins in elderly patients with multiple chronic diseases and liver and/or kidney dysfunction may increase the risk of adverse effects. Our 20-mg per day rosuvastatin group had fewer adverse clinical events, but it is possible the 12-month observation period was not long enough to detect significant differences between the 2 groups. Additionally, longer-term and larger-size clinical observation should be performed to determine whether any additional benefits could be demonstrated. The newly listed lipid-lowering drug PCSK9 inhibitor is a new development in the field of lipid management \[[@b41-medscimonit-26-e925666]\], but it is much more expensive than generic statins, and its cost may impede its clinical application and reduce long-term adherence. Therefore, it is more practical to use less expensive statins for clinical treatment of hypercholesterolemia \[[@b42-medscimonit-26-e925666]--[@b44-medscimonit-26-e925666]\].

Conclusions
===========

Rosuvastatin can significantly reduce serum lipid levels, improve heart function, and reduce the incidence of AF and other cardiovascular events in AMI patients with new-onset AF. The incidence of adverse clinical events was similar in the 2 groups. Smoking and drinking are risk factors for the occurrence of AF and ischemic events. The clinical use of 20 mg rosuvastatin is medically safe within 12 months after hospitalization.
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![Comparison of occurrence of atrial fibrillation (**A**), ischemic events (**B**), and adverse clinical events (**C**) after 12 months of treatment with different dosages of rosuvastatin. Data were compared by log-rank test for the Kaplan-Meier curve.](medscimonit-26-e925666-g003){#f3-medscimonit-26-e925666}

###### 

Baseline characteristics of the two groups.

  Baseline clinical characteristics         10 mg group (n=175)   20 mg group (n=148)   P value
  ----------------------------------------- --------------------- --------------------- ---------
  **Clinical presentation**                                                             
   STEMI \[No. (%)\]                        121 (69.1)            102 (68.9)            0.965
   NSTEMI \[No. (%)\]                       54 (30.9)             46 (31.1)             0.965
   Gender (M/F)                             127/48                109/39                0.828
   Age, years                               63±9                  62±11                 0.676
   BMI (Kg/m^2^)                            25.3±4.2              24.9±3.9              0.468
  **Medical history**                                                                   
   Myocardial infarction \[No. (%)\]        6 (3.4)               7 (4.7)               0.582
   PCI \[No. (%)\]                          8 (4.6)               7 (4.7)               0.999
   Previous stroke/TIA \[No. (%)\]          7 (4.0)               7 (4.7)               0.789
   Previous vascular diseases \[No. (%)\]   7 (4.0)               5 (3.4)               0.999
  **Risk factor**                                                                       
   Hypertension \[No. (%)\]                 70 (40.0)             39 (26.4)             0.010
   Diabetes mellitus \[No.(%)\]             23 (13.1)             29 (19.6)             0.116
   Smoking \[No. (%)\]                      48 (27.4)             46 (31.1)             0.472
   Drinking\[No. (%)\]                      40 (22.9)             41 (27.7)             0.317
  **Current or recent medication**                                                      
   β-blocker \[No. (%)\]                    115 (65.7)            101 (68.2)            0.630
   Calcium-channel blocker \[No. (%)\]      39 (22.3)             35 (23.6)             0.772
   ACEI/ARB \[No. (%)\]                     112 (64.0)            90 (60.8)             0.555
   Diuretic \[No. (%)\]                     20 (11.4)             16 (10.8)             0.861
  **Treatment**                                                                         
   PCI \[No. (%)\]                          152 (86.9)            124 (83.8)            0.435
   Thrombolysis \[No. (%)\]                 13 (7.4)              12 (8.1)              0.820
   Medication \[No. (%)\]                   10 (5.7)              12 (8.1)              0.395

The variables were analyzed by t-test and χ^2^ test.

###### 

Comparison of heart function at admission and after 12 months treatment with different dosages of rosuvastatin.

  index        10 mg group   20 mg group                                                                  
  ------------ ------------- ----------------------------------------------------------------- ---------- --------------------------------------------------------------------------------------------------------------------
  HR (bpm)     92±19         70±7[\*](#tfn3-medscimonit-26-e925666){ref-type="table-fn"}       93±17      68±11[\*](#tfn3-medscimonit-26-e925666){ref-type="table-fn"}
  LVDd (mm)    49.2±7.9      45.7±4.9                                                          50.4±8.1   44.7±6.7
  LVEF (%)     41.3±7.1      54.6±6.8[\*](#tfn3-medscimonit-26-e925666){ref-type="table-fn"}   39.6±4.9   53.4±7.4[\*](#tfn3-medscimonit-26-e925666){ref-type="table-fn"}
  FS (%)       17±6          27±7[\*](#tfn3-medscimonit-26-e925666){ref-type="table-fn"}       18±5       39±7[\*](#tfn3-medscimonit-26-e925666){ref-type="table-fn"}[\#](#tfn4-medscimonit-26-e925666){ref-type="table-fn"}
  CO (L/min)   4.3±1.0       5.8±0.6[\*](#tfn3-medscimonit-26-e925666){ref-type="table-fn"}    4.0±1.2    6.6±0.7[\*](#tfn3-medscimonit-26-e925666){ref-type="table-fn"}

(χ̄±s) The variables were analyzed by ANOVA followed by Tukey's test.

P\<0.05 *vs.* at admission,

P\<0.05 *vs.* 10 mg group.

###### 

Comparison of outcome events after 12 months treatment with different dosages of rosuvastatin.

  Outcome events            10 mg group (n=175)   20 mg group (n=148)   χ^2^ value   *P* value
  ------------------------- --------------------- --------------------- ------------ -----------
  Atrial fibrillation       28 (16.0)             12 (8.1)              4.603        0.032
  Ischemic events           21 (12.0)             8 (5.4)               4.267        0.039
  Adverse clinical events   5 (2.9)               4 (2.7)               0.065        0.799

The variables were analyzed by χ^2^ test and Fisher's exact test.

###### 

Multivariate COX regression of independent factors for the occurrence of atrial fibrillation and ischemic events.

                                   Occurrence of atrial fibrillation   Occurrence of ischemic events                                   
  -------------------------------- ----------------------------------- ------------------------------- ------- ------- --------------- -------
  Group                            0.330                               0.156--0.698                    0.004   0.303   0.128--0.720    0.007
  STEMI/NSTEMI                     1.658                               0.772--3.560                    0.195   0.916   0.403--2.081    0.833
  Gender                           0.679                               0.323--1.426                    0.306   0.525   0.223--1.237    0.140
  Age                              1.045                               1.006--1.085                    0.023   1.000   0.958--1.043    0.984
  BMI                              1.011                               0.933--1.096                    0.787   0.988   0.896--1.089    0.807
  Previous Myocardial infarction   0.970                               0.173--5.442                    0.973   1.986   0.407--9.700    0.396
  Previous PCI                     1.662                               0.486--5.682                    0.418   0.977   0.122--7.825    0.983
  Previous stroke/TIA              1.648                               0.371--7.332                    0.512   1.182   0.151--9.232    0.873
  Previous vascular diseases       1.843                               0.532--6.386                    0.335   3.005   0.661--13.661   0.155
  Hypertension                     0.440                               0.131--1.475                    0.184   0.317   0.062--1.622    0.168
  Diabetes mellitus                0.701                               0.233--2.109                    0.528   2.953   1.169--7.462    0.022
  Smoking                          2.680                               1.383--5.193                    0.003   2.661   1.230--5.755    0.013
  Drinking                         2.285                               1.154--4.525                    0.018   2.097   0.959--4.584    0.064
  β-blocker                        0.520                               0.263--1.027                    0.060   0.508   0.225--1.151    0.105
  Calcium-channel blocker          2.627                               0.759--9.095                    0.127   3.467   0.659--18.247   0.142
  ACEI/ARB                         0.987                               0.484--2.010                    0.971   0.739   0.322--1.696    0.476
  Diuretic                         1.199                               0.454--3.169                    0.714   2.648   0.953--7.358    0.062
  Treatment PCI                    2.898                               0.390--21.553                   0.299   0.491   0.141--1.708    0.263
  Thrombolysis                     2.192                               0.211--22.810                   0.512   0.522   0.078--3.479    0.502

The variables were analyzed by Multivariate Cox analysis.
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